Go Pro
NASDAQ:HURA

TuHURA Biosciences Q2 2026 Earnings Report

TuHURA Biosciences logo
$2.14 +0.04 (+1.90%)
As of 09/4/2026 04:00 PM Eastern

TuHURA Biosciences EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 14, 2026
Conference Call Time
7:30AM ET

Upcoming Earnings

TuHURA Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

TuHURA Biosciences Earnings Headlines

FY2026 Earnings Estimate for HURA Issued By Zacks Research
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
HURA: Milestone Progression Over Next 12 Months
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states. This platform enables the identification of previously unrecognized biological pathways and target proteins, supporting both small‐molecule and biologic drug discovery. The technology is designed to accelerate early‐stage research by revealing disease drivers that traditional genomics and transcriptomics methods may overlook.

TuHURA is advancing a pipeline of programs in areas such as immunology, neurodegeneration and female health. The company has entered research collaborations with pharmaceutical and academic partners to validate targets and co‐develop lead candidates. These partnerships are helping TuHURA expand its reach into therapeutic areas of high unmet medical need while leveraging external expertise and resources.

Founded as a spin‐out from the University of California, Davis technology transfer office, TuHURA Biosciences is headquartered in California and serves a global research community. The company completed its initial public offering on the Nasdaq Capital Market under the ticker HURA in 2022, positioning itself for continued growth and innovation in proteomics‐driven drug discovery.

View TuHURA Biosciences Profile